THE EFFECT OF TAILORED ANTIPLATELET THERAPEUTIC STRATEGY DURING PERCUTANEOUS CORONARY INTERVENTION ON PERIPROCEDURAL MYONECROSIS IN DIABETIC PATIENTS: INSIGHTS FROM THE DM-VERIFYNOW STUDY  by Suh, Jung-Won et al.
Chronic CAD/Stable Ischemic Heart Disease
E1532
JACC March 27, 2012
Volume 59, Issue 13
THE EFFECT OF TAILORED ANTIPLATELET THERAPEUTIC STRATEGY DURING PERCUTANEOUS CORONARY 
INTERVENTION ON PERIPROCEDURAL MYONECROSIS IN DIABETIC PATIENTS: INSIGHTS FROM THE 
DM-VERIFYNOW STUDY
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 11:00 a.m.-Noon
Session Title: DES and Drugs: Decisions in Diabetics
Abstract Category: 3. Chronic CAD/Stable Ischemic Heart Disease: Therapy
Presentation Number: 1209-474
Authors: Jung-Won Suh, Chi-Hoon Kim, Il-Young Oh, Chang-Hwan Yoon, Young-Seok Cho, Tae-Jin Youn, In-Ho Chae, Dong-Ju Choi, Seoul National 
University Bundang Hospital, Seongnam, South Korea
Background: Diabetic patients show poor response to antiplatelet agents and are prone to periprocedural complications during percutaneous 
coronary intervention (PCI) compared to non-diabetic patients. In this study, we investigated the effect of tailored antiplatelet strategy on the 
periprocedural ischemic complications in diabetic patients.
Methods: Study flow is summarized in Figure 1. 130 consecutive diabetic patients were prospectively assigned to 3 study groups from June 2009 
to July 2011. Primary outcome was the incidence of periprocedural MI defined as elevation >3 times upper normal limit of CK-MB or troponin-I 
within 24hrs after PCI. Secondary outcomes were composite of clinical events (death, nonfatal MI, and TIMI major/minor bleeding) at 1 month.
Results: 98 Patients (75.4%) showed HPPR among 130 patients enrolled to this study. Clinical and procedural characteristics were not different 
among three groups. There were no significant differences in the rate of periprocedureal MI (test group, 57.4%; control 1, 56.9%; control 2, 50.0%, 
p=0.78). Bleeding events were more frequent in test group (test group, 10.6%; control 1, 2.0%; control 2, 0%, p=0.04), No other adverse events 
were reported during the follow-up.
Conclusion: 75.4% of diabetic patients could not achieve adequate platelet inhibition with loading of 300mg clopidogrel one day before PCI. 
Additionally, tailored approach using abciximab to diabetic patients with HPPR did not decrease periprocedural ischemic complications.
